Global Castration Resistant Prostate Cancer Treatment Market Size, Status and Forecast 2020-2026

Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
North America dominates the global market for castration resistant prostate cancer treatment due to presence of large prostate cancer population in this region. Moreover, increasing demand of diagnostic test, increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global castration resistant prostate cancer treatment market due to presence of large geriatric population base in European region. Asia-Pacific is considered as an untapped market due to lack of awareness and lack of proper healthcare facilities in some Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Similarly, Asia-Pacific is considered as an emerging market during the study period due to growing market penetration in this region.

Market Analysis and Insights: Global Castration Resistant Prostate Cancer Treatment Market
The global Castration Resistant Prostate Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Castration Resistant Prostate Cancer Treatment Scope and Market Size
Castration Resistant Prostate Cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Castration Resistant Prostate Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study

Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals

Market segment by Type, the product can be split into

Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others

Market segment by Application, split into

Hospital
Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India

Frequently Asked Questions